Advice on Decision Making for Frontline Treatment of HCC
In Partnership With
Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma.
Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma (HCC).
According to Zhu, most clinicians base these decisions off the best available data. If the overall survival (OS) difference is available, that will guide clinicians in choosing one agent over another.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
